Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 13Colorectal Neoplasms 10Neoplasm Metastasis 4Lung Neoplasms 4Colonic Neoplasms 4Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Renal Cell 2Solid Tumors 1Resectable Non-Small Cell Lung Cancer 1Rectal Neoplasms 1Kidney Neoplasms 1Brain Neoplasms 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lung Neoplasms × adagrasib × 1 year × Clear all
NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Not yet recruiting
29 enrolled
Thoracic

Lung Neoplasms

NCT06497556 2026-04-20

Krascendo 1

Hoffmann-La Roche

Phase 3 Active not recruiting
338 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

City of Hope Medical Center

Phase 2 Recruiting
535 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05853575 2026-03-27

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Mirati Therapeutics Inc.

Phase 2 Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡